Acquired Company

Pathos AI completed the acquisition of Rain Oncology Inc. for $1.16 per share in cash plus one contingent value right.

Rain Enhancement Technologies Holdco, Inc. develops, manufactures, and commercializes ionization rainfall generation technology. It plans to develop improvements on existing rainfall generation technologies by introducing robust measurement tools, including software monitoring technology, machine learning, rain gauges, and weather stations. The company was founded in 2022 and is headquartered in Naples, Florida. Show more

Location: 4851 Tamiami Trail N, Naples, FL, 34103, United States | Website: https://rainwatertech.com | Industry: Pollution & Treatment Controls | Sector: Industrials

Market Cap

23.75M

52 Wk Range

$1.75 - $9.58

Previous Close

$2.90

Open

$2.80

Volume

8,994

Day Range

$2.77 - $2.95

Enterprise Value

30.51M

Cash

236.7K

Avg Qtr Burn

-695.1K

Insider Ownership

73.61%

Institutional Own.

8.90%

Qtr Updated

09/30/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Milademetan (RAIN-32) w/ atezolizumab Details Solid tumor/s, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Milademetan (Rain-32) Details Solid tumor/s, Cancer, Carcinoma , Metastatic merkel cell carcinoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Milademetan (Rain-32) Details Liposarcoma, Cancer, Solid tumor/s	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Milademetan (RAIN-32) Details Solid tumor/s, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.

We track quarterly 13F filings for some of the largest biotech hedge funds here.